San Francisco — Patients with non-alcoholic fatty liver disease carried a 91% higher risk for malignancy and the risk for cancer with obesity is “driven by NAFLD,” according to a presentation at The Liver Meeting 2018. “The risk of malignancy…
Study finds fatty liver disease is less likely to occur in mothers who breastfeed for more than six months. Researchers at UC San Diego School of Medicine and Kaiser Permanente have discovered that mothers who breastfed a child or children…
Naglaa Shoukry, Ph. D., and her team have made a significant breakthrough in their research aiming to limit the progression of liver disease. They have characterized the mechanisms of action of type 3 inflammatory cytokines that are produced by the…
Sarcopenia, defined as the loss of muscle mass associated with aging, is present in more than 30% of elderly persons and observed worldwide. Not surprisingly, a greater prevalence of sarcopenia is noted in patients residing in nursing homes.
While liver biopsies are powerful and reliable, they are also invasive, painful, limited and subject to complications. These effects may soon be a thing of the past for some patients thanks to new research showing PET imaging with the F-FAC radiotracer can be used as a non-invasive substitute.
08 October 2018, Geneva, Switzerland: On 17 September, 2018, Prof. Philip Newsome was unanimously nominated to the position of EASL Vice-Secretary, taking over from Prof. Frank Tacke who stepped down from this position in order to pursue new academic challenges.
A new study found a web-based intervention to be an effective and convenient approach to manage lifestyle changes in patients with NAFLD, reports the Journal of Hepatology.
Geneva, Switzerland, 20 September 2018 - The EASL Nonalcoholic Fatty Liver Disease (NAFLD) Summit commenced today at the Starling Hotel Conference Centre in Geneva, Switzerland, attended by over 300 basic and clinical researchers, industry, and renowned specialists from around the world.
Physicians and researchers have noted the increase in liver disease over the last couple decades, especially nonalcoholic fatty liver disease, correlates significantly with the increase in obesity and overweight.
Research reveals that an existing drug used to treat liver disease could also be employed in Alzheimer's disease therapy. The drug "heals" malfunctioning elements at cellular level.